156 related articles for article (PubMed ID: 32656765)
1. Fine-tuning the treatment toolbox of immune thrombocytopenia: fostamatinib as a second-line therapy.
Kapur R
Br J Haematol; 2020 Sep; 190(6):817-818. PubMed ID: 32656765
[No Abstract] [Full Text] [Related]
2. Fostamatinib is an effective second-line therapy in patients with immune thrombocytopenia.
Boccia R; Cooper N; Ghanima W; Boxer MA; Hill QA; Sholzberg M; Tarantino MD; Todd LK; Tong S; Bussel JB;
Br J Haematol; 2020 Sep; 190(6):933-938. PubMed ID: 33439486
[TBL] [Abstract][Full Text] [Related]
3. Long-term sustained response to fostamatinib in two patients with chronic refractory immune thrombocytopenia (ITP).
Lee EJ; Izak M; Bussel JB
Br J Haematol; 2020 Apr; 189(2):379-382. PubMed ID: 31900937
[TBL] [Abstract][Full Text] [Related]
4. Fostamatinib for the treatment of chronic immune thrombocytopenia.
Connell NT; Berliner N
Blood; 2019 May; 133(19):2027-2030. PubMed ID: 30803989
[TBL] [Abstract][Full Text] [Related]
5. Fostamatinib for the treatment of immune thrombocytopenia in adults.
Moore DC; Gebru T; Muslimani A
Am J Health Syst Pharm; 2019 May; 76(11):789-794. PubMed ID: 30951590
[TBL] [Abstract][Full Text] [Related]
6. Real-World Use of Fostamatinib in Patients with Immune Thrombocytopenia and Thrombotic Risk.
Mehta AR; Kefela A; Toste C; Sweet D
Acta Haematol; 2022; 145(2):221-228. PubMed ID: 34913873
[TBL] [Abstract][Full Text] [Related]
7. Spleen tyrosine kinase inhibition: a new promising approach to chronic and refractory immune thrombocytopenia.
Niscola P; Scaramucci L; Giovannini M
Immunotherapy; 2018 Jan; 10(1):5-7. PubMed ID: 29192558
[No Abstract] [Full Text] [Related]
8. Evaluating fostamatinib disodium as a treatment option for immune thrombocytopenia in adult patients.
Dierickx D; Neefs J
Expert Opin Pharmacother; 2022 Jun; 23(8):885-892. PubMed ID: 35621338
[TBL] [Abstract][Full Text] [Related]
9. Fostamatinib: First Global Approval.
Markham A
Drugs; 2018 Jun; 78(9):959-963. PubMed ID: 29869203
[TBL] [Abstract][Full Text] [Related]
10. Fostamatinib for the treatment of Japanese patients with primary immune thrombocytopenia: A phase 3, placebo-controlled, double-blind, parallel-group study.
Kuwana M; Ito T; Kowata S; Hatta Y; Fujimaki K; Naito K; Kurahashi S; Kagoo T; Tanimoto K; Saotome S; Tomiyama Y;
Br J Haematol; 2023 Mar; 200(6):802-811. PubMed ID: 36470677
[TBL] [Abstract][Full Text] [Related]
11. Fostamatinib for persistent/chronic adult immune thrombocytopenia.
Newland A; Lee EJ; McDonald V; Bussel JB
Immunotherapy; 2018 Jan; 10(1):9-25. PubMed ID: 28967793
[TBL] [Abstract][Full Text] [Related]
12. Long-term treatment with fostamatinib in Japanese patients with primary immune thrombocytopenia: An open-label extension study following a phase 3 placebo-controlled, double-blind, parallel-group study.
Kuwana M; Ito T; Kowata S; Hatta Y; Fujimaki K; Naito K; Kurahashi S; Kagoo T; Tanimoto K; Saotome S; Tomiyama Y
Am J Hematol; 2024 Feb; 99(2):E55-E59. PubMed ID: 38165064
[No Abstract] [Full Text] [Related]
13. Fostamatinib disodium hexahydrate: a novel treatment for adult immune thrombocytopenia.
McBride A; Nayak P; Kreychman Y; Todd L; Duliege AM; Mehta AR
Am J Manag Care; 2019 Nov; 25(19 Suppl):S347-S358. PubMed ID: 31809006
[TBL] [Abstract][Full Text] [Related]
14. Treatment with fostamatinib in patients with immune thrombocytopenia: Experience from the Andalusian region in Spain-The Fostasur Study.
Jiménez-Bárcenas R; García-Donas-Gabaldón G; Campos-Álvarez RM; Fernández-Sánchez de Mora MC; Luis-Navarro J; Domínguez-Rodríguez JF; Nieto-Hernández MDM; Sánchez-Bazán I; Yera-Cobo M; Cardesa-Cabrera R; Jiménez-Gonzalo FJ; Ruiz-Cobo MA; Caparrós-Miranda I; Entrena-Ureña L; Fernández Jiménez D; Díaz-Canales D; Moreno-Carrasco G; Calderón-Cabrera C; Núñez-Vázquez RJ; Pedrote-Amador B; Mingot-Castellano ME;
Br J Haematol; 2024 May; 204(5):1977-1985. PubMed ID: 38566598
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis.
Yang R; Lin L; Yao H; Ji O; Shen Q
Hematology; 2019 Dec; 24(1):290-299. PubMed ID: 30661482
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and effects of novel thiazole derivatives against thrombocytopenia.
Tsuji K; Ogino T; Seki N; Sawada M; Sudo Y; Nishigaki F; Manda T; Matsuo M
Bioorg Med Chem Lett; 1998 Sep; 8(18):2473-8. PubMed ID: 9873564
[TBL] [Abstract][Full Text] [Related]
17. Platelet recovery with ibrutinib therapy in patient with treatment-refractory immune thrombocytopenia.
Parish PC; Moore DC; Arnall J; Howell TJ; Dick B; Cambareri R
Ann Hematol; 2023 Jan; 102(1):237-238. PubMed ID: 36441261
[No Abstract] [Full Text] [Related]
18. Methylprednisolone-induced immune thrombocytopenia.
Royer B; Lee K; Gruson B; Roszkiewicz F; Al Khedr A; Colson A; Camboulives A; Bierling P; Marolleau JP
Blood; 2010 Jul; 115(26):5431-2. PubMed ID: 20595525
[No Abstract] [Full Text] [Related]
19. Fostamatinib, a Syk inhibitor prodrug for the treatment of inflammatory diseases.
Bajpai M
IDrugs; 2009 Mar; 12(3):174-85. PubMed ID: 19333898
[TBL] [Abstract][Full Text] [Related]
20. Fostamatinib (Tavalisse) for ITP.
Med Lett Drugs Ther; 2019 Feb; 61(1566):28-30. PubMed ID: 30845102
[No Abstract] [Full Text] [Related]
[Next] [New Search]